Today in Biology — Aug 10

[SOFIA] Okay, so a seismic shift just happened in how big biology projects are getting funded and, honestly, where a lot of the engineering biology action is going to be in the next few years. Last week, the Department of Energy’s Genesis Mission committed five *billion* dollars and announced 278 new projects. Five billion! That’s a huge amount of capital flowing into very specific areas.

[DANIEL] It’s certainly a notable figure, Sofia. And it’s not just the sum, but the focus. This Genesis Mission is heavily weighted towards AI for science, particularly within the national lab system. Savannah River National Lab, for instance, just secured funding for AI-powered cleanup projects. And NIST, the National Institute of Standards and Technology, has officially joined Genesis to accelerate AI innovation, specifically on the measurement and standardization side of things.

[SOFIA] Right, and that NIST piece is actually pretty critical for engineering biology. When we're talking about AI-driven discovery, especially for things like optimizing bioproduction or designing new enzymes, you *need* incredibly robust, standardized datasets. AI is only as good as the data it trains on. If NIST is stepping in, it’s a strong signal that the DOE is serious about the foundational infrastructure needed to make AI for science truly effective, not just a buzzword. For those of us building tools, this means better benchmarks, more reliable data, and hopefully, less time wrestling with inconsistent formats. [DDANIEL] A move towards greater standardization is always welcome. My concern, however, is the sheer volume of projects announced at once — 278 projects from 5,000 applications. While it indicates significant interest and a broad base of funding, ensuring rigor and meaningful impact across such a large portfolio, especially with a novel emphasis like AI for science, presents a substantial challenge for oversight and evaluation. It will be critical to see how the DOE implements mechanisms to track progress and ensure the stated goals are met, rather than simply dispersing funds.

[SOFIA] Totally. And it’s a stark contrast to what we’re seeing over at the NIH. While DOE is going big and bold, the NIH just announced it still has over ten billion dollars left in its budget with only a few weeks to go until the end of the fiscal year. And Director Bhattacharya is reportedly cutting more health disparities grants.

[DANIEL] That latter point is particularly concerning. Terminating grants, especially those focused on health disparities, signals a shift in priorities that warrants close attention. It raises questions about the NIH’s strategic direction and its commitment to a broad spectrum of public health needs, particularly when juxtaposed with the substantial unspent funds. The implications for researchers relying on these grants, and for the populations they serve, are significant.

[SOFIA] Exactly. And then, there's a whisper of potential legislative interference. *Nature* reported that a White House plan to overhaul US science funding is facing Senate opposition, with a draft spending bill that could temporarily halt these kinds of big policy shifts. So, while DOE is pushing hard into AI and national lab biology, NIH seems to be in a holding pattern, and there's a big political question mark hanging over everything. It makes you wonder how much stability there's going to be for long-term projects.

[DANIEL] Indeed. The confluence of these factors – a massive, targeted investment by DOE, the apparent inertia and shifting priorities at NIH, and the potential for legislative intervention – creates an unusually dynamic, and perhaps unpredictable, funding landscape for the life sciences. Researchers will need to be particularly strategic in navigating these shifting currents.